Celgene Corporation to acquire Juno Therapeutics, building global leadership in cellular immunotherapy
Celgene Corporation will acquire Juno Therapeutics, it has been announced as the two companies have signed a merger agreement.
Pharmaceuticals, Biotechnology and Life Sciences
Celgene Corporation will acquire Juno Therapeutics, it has been announced as the two companies have signed a merger agreement.
In addition to today’s news about Yervoy in combination with Opdivo , Bristol-Myers Squibb said today that the European Commission (EC) has…
Bristol-Myers Squibb Company today said that new data from a cohort of the phase 2 CheckMate -142 test of the…
Sanofi will buy Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, for $11,6…
Bavarian Nordic said Friday that it has kicked off a clinical trial of BN-Brachyury, a novel cancer immunotherapy candidate designed…
AstraZeneca and its global biologics research and development arm, MedImmune, said on Friday that the Japanese Ministry of Health, Labour…
AstraZeneca and Merck have announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg…
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company,…
STADA Arzneimittel AG is advancing the internationalization of its OTC brand business. On January 12, 2018, the company reached an…
West-Ward Pharmaceuticals, wholly-owned Hikma Pharmaceuticals’s US subsidiary has launched Ifosfamide Injection, 1g/20mL vials, the generic equivalent to Ifex.